⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289691 | 1.00 | — | — | |
| SCHEMBL2050871 | 1.00 | — | — | |
| SCHEMBL895275 | 0.97 | — | — | |
| SCHEMBL186897 | 0.97 | — | — | |
| SCHEMBL1771875 | 0.94 | — | — | |
| SCHEMBL1771877 | 0.94 | — | — | |
| SCHEMBL3619266 | 0.94 | — | — | |
| SCHEMBL3265617 | 0.94 | — | — | |
| SCHEMBL31154658 | 0.94 | — | — | |
| SCHEMBL31252519 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083796-B | Trisubstituted 3, 4-dihydro-1H-isoquinoline compounds, process for their preparation, and their use | ACTELION PHARMACEUTICALS LTD | 2013-06-05 | — | — | CN | claimed |
| CN-102026979-B | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD | 2013-05-08 | — | — | CN | claimed |
| CN-102083796-A | Trisubstituted 3, 4-dihydro-1H-isoquinoline compounds, process for their preparation, and their use | ACTELION PHARMACEUTICALS LTD | 2011-06-01 | — | — | CN | claimed |
| CN-102026979-A | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD | 2011-04-20 | — | — | CN | claimed |
| CN-113354649-B | Novel crystal form | 阵列生物制药公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-113195801-B | Crystal, method for producing crystal, and method for self-assembling silanol compound | 国立研究开发法人产业技术综合研究所 | 2024-10-15 | — | — | CN | disclosed |
| EP-3439663-B1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-109414442-B | Liquid preparation of compound | 洛克索肿瘤学股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230026258-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | UDC IRELAND LTD (IE) | 2023-01-26 | — | — | US | disclosed |
| US-11484535-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | LOXO ONCOLOGY, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-2427465-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-102164903-A | Synthesis routes to 2(S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides | DSM IP ASSETS BV | 2011-08-24 | — | — | CN | disclosed |
| CN-102083796-A | Trisubstituted 3, 4-dihydro-1H-isoquinoline compounds, process for their preparation, and their use | ACTELION PHARMACEUTICALS LTD | 2011-06-01 | — | — | CN | disclosed |
| CN-102026979-A | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD | 2011-04-20 | — | — | CN | disclosed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | disclosed |
| CN-101528699-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-09-09 | — | — | CN | disclosed |